TG Therapeutics Inc (NAS:TGTX)
$ 16.48 -0.94 (-5.4%) Market Cap: 2.55 Bil Enterprise Value: 2.45 Bil PE Ratio: 74.91 PB Ratio: 15.91 GF Score: 75/100

TG Therapeutics Inc to Discuss UNITY-CLL Phase 3 Trial Conference Call Transcript

May 05, 2020 / 12:30PM GMT
Release Date Price: $16.69 (+33.95%)
Operator

Greetings, and welcome to the TG Therapeutics Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Jenna Bosco. Please go ahead, ma'am.

Jenna Bosco
TG Therapeutics, Inc. - VP of IR & Senior VP of Corporate Communications

Good morning, and thank you all for joining us today to discuss the positive topline results from the UNITY-CLL Phase III trial. I'm Jenna Bosco, TG's Senior Vice President of Corporate Communications, and I welcome you to our conference call today.

Following our safe harbor statement, Michael Weiss, the company's Executive Chairman and Chief Executive Officer, will review the topline results from the UNITY trial, and then turn the call over to Dr. Javier Pinilla, the Lymphoma Section Head and Director of Immunotherapy at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and one of our leading enrollers in the UNITY-CLL trial, who will reflect on today's outcome and provide an overview of his

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot